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ACCESS TO INVESTIGATIONAL
TREATMENTS
Mary Ader*
I. THE ISSUE
STRFE OVER THE SCOPE of health benefits persists. It
permeates our courts, our legislatures, and our lives, eluding
satisfactory solutions. Each day health plans are called on to de-
sign, draft, administer, and defend their benefit contracts in the
face of astonishing technological advances, vigilante consumer-
ism, and unprecedented judicial and legislative intervention. No-
where is the controversy over coverage more acute than over ac-
cess to investigational treatments.
Many factors have fueled this controversy. First, health plan
beneficiaries, often with life-threatening diseases, expect their
health plans to pay for potentially life-saving treatments, even
though these treatments are still under investigation in various
research programs. When health plans invoke the investigational
exclusion to deny coverage, and balk at financing medical re-
search (as opposed to paying for mainstream medical care), then
the plan beneficiary may well choose to litigate the issue. Sec-
ond, researchers and providers of care, faced with dwindling re-
search revenues from other sources, are anxious to acquire third-
party payment to help support their medical research. And third,
state legislatures often resort to enacting mandated benefits legis-
lation requiring third-party payors to pay for such research.
Historically, health plans have generally paid only for treat-
ment that works, not for medical research. Perhaps it is now time
for health plans to reassess this position, to help resolve the con-
troversies over emerging technology, not through the courts and
legislatures on an ad hoc basis, but rather through supporting the
quest for scientific evidence through clinical trials. This approach
would seem to be more constructive, more systematic. This Arti-
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cle examines some of the legal and medical issues involved in
this debate, and offers some suggestions for future directions and
conflict resolution.
II. THE OBJECTIVE
Our imperative is to chart a rational course to which all in-
terested parties can subscribe - researchers and providers,
payors and arrangers, patients and policyholders, lawyers and
legislators. The objective is to establish a modus vivendi that ac-
knowledges and addresses all their respective concerns. This un-
dertaking, however, is far more complex than many of us may
realize. It requires us to synthesize science, law, and public pol-
icy, and to put science first and foremost. This kind of preemp-
tion may be discomforting to some, particularly those accus-
tomed to legal leveraging. Nevertheless, it requires us all to
submit to the authority - indeed the supremacy - of scientific
data over legislative, journalistic, and judicial pronouncements.
III. THE CONTEXT
The ability to manage access to emerging medical technol-
ogy is critical both to society in general and also to the three
main parties to the health care transaction - patient, provider,
and payor. It is critical in three different ways. First, it is critical
to managing the delivery of quality medical care. We must de-
liver care that helps the patient, not care that may hurt the pa-
tient. We must ensure that the benefits of the treatment outweigh
the harms. Second, it is critical to managing the financial con-
straints of delivering a quality health care benefit. We must be
able to deliver the benefit within the budget (the premiums col-
lected for the contracts issued). Third, it is critical to managing
the legal risks of the failure to describe the benefits accurately
and deliver them efficiently. Therefore, in the interests of quality
medical care, delivered on budget, beyond legal challenge, it is
prudent to develop criteria and mechanisms for determining ac-
cess to investigational treatments.
In developing these principles of access to investigational
treatment, we must recognize that in any rational health care sys-
tem, there are limits on affordability. This creates at least two
fundamental tensions. First, there is the tension between the insa-
tiable demand for new technology and the need to establish -
scientifically - safety and efficacy prior to diffusion. There is a
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risk that our capacity to demand new technology may now be
outpacing our capacity to assess its clinical usefulness. Second,
there is the tension between the availability of these technologi-
cal advances and their attendant costs. Our capacity to produce
new technology may now be outpacing our capacity to pay for
it. So we have to set reasonable limits. How to capture the bene-
fit of new technology, and not lose it amidst budgetary con-
straints, presents both a challenge and an opportunity to the pro-
ponents of managed care.
IV. THIRD-PARTY PAYOR RESPONSES
Third-party payors have attempted to set reasonable limits in
two major ways. The first method is a greater reliance on tech-
nology assessment. Payors, and their accounts, want value for
their money. They want to pay for what works. Technology as-
sessment is one means to this end. Technology assessment is per-
formed by about seventy organizations nationwide: the major in-
surers do it; as do some medical societies; the federal
government; and various research organizations. The key product
is a secondary medical technology assessment that consists of a
document that summarizes the current state of knowledge con-
cerning the technology in question, including divergent evidence,
areas of controversy, and gaps in the knowledge base. It de-
scribes safety, efficacy, and appropriate use based on the availa-
ble evidence. If there is insufficient scientific evidence from
which to draw conclusions as to safety and efficacy and as to
improvement in health outcomes - such as length of life, ability
to function, and quality of life - then payors and their accounts
are likely to require the development of such evidence before the
technology flows into mainstream payment.
In this way, technology assessment addresses not the cost of
emerging technologies, but more significantly, value for money.
The vital role that technology assessment plays in determining
sound medical policy has generally been underrated, and some-
times even ignored or flouted by courts and legislatures. We
need to make more effort to prevent these oversights, to make
the process of technology assessment intelligible to a wider audi-
ence, and to educate the populace about this pivotal means of
delivering quality health care.
The second method of defining reasonable limits has been
for payors to tighten and enforce their exclusions from coverage,
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particularly their investigational and medical necessity exclu-
sions. These two exclusions, and the concepts that they represent,
are sometimes confused, and sometimes used interchangeably.
However, they do serve different, but equally valid, purposes.
Medical necessity exclusions, in essence, address the issue
of the appropriateness of care for a given diagnosis, including
the appropriate level of care. For example, does this diagnosis
require six months of acute hospital care? In this length of stay
medically necessary? Most medical necessity lawsuits are, in
fact, length of stay disputes, and happen to be mostly psychiat-
ric.' What this suggests is that there may be more uncertainty
over the diagnosis and treatment of mental illness than there is
over the concept of medical necessity as such. The definitional
problem lies in the term "mental illness," not in "medical ne-
cessity." Although the concept of medical necessity has been
much maligned, it does attempt to address the important concept
of efficiency.
Investigational exclusions, by contrast, are designed to ad-
dress the issues of safety and efficacy. They should do this by
looking to the status of the technology. The language of the ex-
clusion should, therefore, contain objective criteria that correlate
to the existence of the continuing investigation of the technology.
The question to be answered is: given this patient and this diag-
nosis, is there enough evidence to establish that this treatment
works? Or is the evidence still being developed? Still inconclu-
sive? If the procedure is still under investigation, it is investiga-
tional, warranting the Scottish verdict, "not proven." Technology
assessments, when available, should determine the outcome of
this inquiry. In terms of coverage, most accounts do not want to
pay for technologies that have not yet proven their value. In
terms of public policy and the need to conduct promising medi-
cal research, we need to develop means of financing patient ac-
cess to such research.
1. See, e.g., Hughes v. Blue Cross, 248 Cal. Reptr. 172 (1988); cert. denied, 110 S. Ct.
2200 (1990); Salley v. E.I. DuPont & Co., 966 F. 2d 1011 (5th Cir. 1992). A significant med-
ical necessity case that did not involve psychiatric treatment is Katskee v. Blue Cross and
Blue Shield, No. 5-92-1022 (Neb. Sup. Ct, May 6, 1994). The plaintiff had a genetic predis-
position to cancer - breast-ovarian carcinoma syndrome - and the court found that this was
an "illness" within the meaning of the contract, and that radical prophylactic surgery to re-
move the uterus, ovaries and fallopian tubes should not be denied on medical necessity
grounds.
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V. THE IMPACT OF ASSESSMENTS AND EXCLUSIONS
When third-party payment is not forthcoming by virtue of
an assessment or exclusion, what impact does this have on the
technology, and on the quality of care? First, payment decisions
based on technology assessments and/or benefit exclusions may
in fact delay the diffusion of technologies eventually found to be
medically appropriate.2 Sometimes there are prolonged periods of
uncertainty for technologies eventually proven to be beneficial
(cochlear implants for children for example). This occurs even
though payors are committed to paying quickly to please their
customers, and to the improvement of the quality of their ser-
vices. Second, and conversely, the benefits of new technologies
may ultimately prove to be small or nonexistent. Here, the deci-
sion to pay may promote ineffective or even harmful technolo-
gies (for instance, thalidomide; bowel removal for epilepsy; the
freezing of gastric ulcers; and the Garren gastric bubble). Safety
should always be the first consideration.
Finding the right balance is not always straightforward, and
can be controversial. Currently, a number of technologies seem
to fall into a "grey" area of payment confusion and litigation,
such as high-dose chemotherapy with autologous bone marrow
transplant (HDC-ABMT) for breast cancer; growth hormones for
short-statured children; home uterine monitoring to detect early
labor; PET scans; 3 and radial keratotomy.4 Tomorrow's technolo-
gies, such as gene therapy, are already on the horizon. Does
every technological advance have to be accompanied by payment
battles, played out in the courts and the media? Surely these are
singularly inappropriate forums for determining access to investi-
gational treatments, given the nature of the scientific issues that
such treatments present.
VI. ACCESS THROUGH LITIGATION
During the past few years, hundreds of patients have sought
2. Given a choice of possible treatments, providers generally opt for the one that the
third-party payor reimburses. Therefore, until the newer technologies are proven safe and ef-
fective and hence, reimbursable, providers are reluctant to prescribe them.
3. Positron Emmission Tomography (PET) uses a radioactive isotope to show areas of
brain activity.
4. Radial keratotomy is a refractive surgery for the permanent correction of myopia
(nearsightedness) and/or astigmatism.
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access to investigational treatments through the courts.5 Many of
these patients have been successful, for a variety of reasons, in-
cluding the sympathy factor, inadequate and ambiguous contract
language, and alleged negligent medical review by the benefit
plan.6 As a result of this litigation compelling access to investi-
gational treatments, benefit plans have tightened their exclusion-
ary language and strengthened their medical review processes.
Nevertheless, the litigation continues, leaving unanswered
some fundamental questions. Should health plans exclude investi-
gational treatment to begin with? If so, how should health plans
define "investigational?" How should they determine whether a
particular treatment meets the definition? To health care payors,
it seems that these questions have been the subject of much mis-
understanding to those outside the health care payment business
- patients, providers, the media, and the courts.
However, on certain key points the cases are instructive,
and send a clear message to health plans that if they wish to ex-
clude investigational treatments, their investigational exclusions
need to contain, at a minimum, four elements: (i) sound criteria
for making the decisions; (ii) a description of the decision-
making process; (iii) language that is not ambiguous; and (iv)
language that is sufficient to put the subscriber on notice of what
is and what is not covered. 7 This is easier said than done. To
courts called upon to review complex medical and methodologi-
cal questions, ambiguity in contract language will be construed
against payors. Therefore, what is meant by "investigational"
needs to be precisely defined in the contract and specifically re-
lated to enforceable criteria.
5. See, e.g., Harris v. Blue Cross and Blue Shield, 729 F. Supp. 49 (N.D. Tex. 1991);
Cole v. Blue Cross and Blue Shield, 738 F. Supp. 42 (D. Mass. 1990). For an extensive com-
pilation of these cases, see ADER & Lewis, INVSnGATIONAL EXCLUSIONS: A SUMMARY o THE
CASHLAW (1995).
6. Where the plaintiff is seeking treatment for a life-threatening disease and the defend-
ant is a deep-pocket defendant such as an insurance company, these facts tend to influence
the outcome of litigation, regardless of the contract language at issue. In this David versus
Goliath context, courts have often found the contract language ambiguous, see Bailey v. Blue
Cross & Blue Shield, 866 F. Supp. 227 (E.D. Va. 1994), or found the medical review process
deficient or inadequate in some way, see, e.g., Bucci v. Blue Cross & Blue Shield, 764 F.
Supp. 728 (D. Conn. 1991). See also ADER & LEwis, supra note 5.
7. See, e.g., Dozsa v. Crm & Forster, 716 F. Supp. 131 (D. NJ. 1989); Hurowitz v.
Blue Cross & Blue Shield, No. 90-451 (E.D. Va. 1990); Waldrip v. Connecticut Mut. Life
Ins. Co., 566 So. 2d 434 (La. App. 1990). See also ADER & LEwis, supra note 5.
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Health plans have adopted different approaches to the prob-
lem of how to develop standards or criteria for determining in-
vestigational status. Some are better than others, but all have
fallen victim to judicial disapproval at some time or another. The
first approach is to accept the standard of "professional consen-
sus." This, however, runs the risk of becoming the consensus of
the relevant professionals, which in turn may become the con-
sensus of the treatment's proponents.8 From the payor's perspec-
tive, this is a slippery slope.
A second approach is to reference and adopt the positions
of other entities, such as the federal Office of Technology As-
sessment, the National Institutes of Health, or the AMA. This,
too, is problematical. The entity selected may not have a position
on a particular technology; the entity's position may be unclear,
out-of-date, or in conflict with the position of other entities; and
the subscriber still may not receive adequate notice of what is or
is not covered.9
The third approach is to use scientific criteria, such as those
used in the technology assessment program of the Blue Cross
and Blue Shield Association.' 0 This approach recognizes that
8. See Dozsa, 716 FSupp. at 131.
9. Waldrip, 566 So. 2d at 434.
10. The five Blue Cross and Blue Shield Association TEC criteria are:
1. The technology must have final approval from the appropriate government regulatory
bodies.
" This criterion applies to drugs, biological products, devices and diagnostics.
" A drug or biological product must have final approval from the Food and Drug
Administration.
- A device must have final approval from the Food and Drug Administration for those
specific indications and methods of use that Blue Cross and Blue Shield Association is
evaluating.
° Any approval that is granted as an interim step in the FDA regulatory process is not
sufficient.
2. The scientific evidence must permit conclusions concerning the effect of the technol-
ogy on health outcomes.
- The evidence should consist of well-designed and well-conducted investigations pub-
lished in peer-reviewed journals. The quality of the body of studies and the consistency of the
results are considered in evaluating the evidence.
- The evidence should demonstrate that the technology can measure or alter the physio-
logical changes related to a disease, injury, illness, or condition. In addition there should be
evidence or a convincing argument based on established medical facts that such measurement
or alteration affects the health outcomes.
- Opinions and evaluations by national medical associations, consensus, or other technol-
ogy evaluation bodies are evaluated according to the quality of the supporting evidence and
rationale.
3. The technology must improve the net health outcome.
- The technology's beneficial effects on health outcomes should outweigh any harmful
Winter 1996]
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there is a difference between the systematic generation of objec-
tive data and authoritative opinion. The latter may prevail in
lawsuits in the short run, but must inevitably yield to the former
in the long run."
For health plans that want to cover only those treatments
proven to work, the scientific criteria approach, geared to the
systematic generation of objective data, appears to be the supe-
rior one. Such plans would presumably specifically -exclude treat-
ments performed in Phase I, II, or 1II clinical trials under proto-
cols that reference determinations of safety, efficacy, toxicity,
and comparisons to conventional alternatives; and treatments that
called for Institutional Review Board (IRB) approval and consent
to investigational treatment.
Regardless of a health plan's approach and objective, its
contract language will always be at risk of legal challenge on
grounds of ambiguity, and its medical review process on grounds
of timeliness, comprehensiveness, and currency. The burden of
vigilance here, the courts say, falls on the health plan. 12 All of
effects on health outcomes.
4. The technology must be as beneficial as any established alternatives.
- The technology should improve the net health outcome as much as or more than estab-
lished alternatives.
5. The improvement must be attainable outside the investigational settings.
- When used under the usual conditions of medical practice, the technology should be
reasonably expected to satisfy criteria #3 and #4.
11. Some courts have decried the health plans' failure to specify the quantum of evi-
dence required, and have called for specific thresholds of statistical success in terms of cure
or survival rates. See Pirozzi v. Blue Cross & Blue Shield, 741 F. Supp. 586 (E.D. Va. 1990);
Reiff v. Blue Cross & Blue Shield, No. CIV 90-583-S (E.D. Okla., 1991); Bucci, 764 F.
Supp. at 728. With all due respect to these courts, such a standard - for all diseases, all
technologies, and all times - simply could not be met; it would be utterly impracticable
even to attempt to embrace all these in a single health benefit contract. Although these partic-
ular courts condemned the lack of standards for determining statistical success, at least one
other court, looking at the numbers, took a different view. Evans v. HMO Col., Inc., No. 91
CV 3797 (Colo. Dist. Ct., 1991). Here, the plaintiff sought benefits for HDC-ABMT for the
treatment of cervical cancer. The court found it significant that the procedure had been per-
formed on only six patients at one research facility. It said: "The University of Nebraska is
the only one that has been trying to find out if this is going to work on this kind of solid
cancerous form . ... [Niobody knows yet. Everybody agrees that six is far too few to make
a judgment on."
Ironically, "going by the numbers" has been condemned by one court. In reviewing in
vitro fertilization, a court found it arbitrary and capricious for a plan to grant or deny cover-
age based solely on a success ratio (in this case, less than 50% successful). Reilly v. Blue
Cross & Blue Shield United, 846 F.2d 416 (7th Cir. 1988).
12. Contract language does not always contemplate new medical developments. See,
e.g., Bailey, 866 F. Supp. at 277; Calhoun v. Complete Health Inc., No. 94-556, 1994 WL
448986 (S.D. Ala. 1994); McLaughlin v. Williams, 801 F. Supp. 633 (S.D. Fla. 1992).
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this makes access to investigational treatment through litigation
unpredictable and costly. Worse, the clinical issues of safety and
efficacy are lost through loophole lawyering that focuses on how
to interpret a benefit, not how to benefit an insured.
VII. BEYOND LITIGATION: ACCESS TO CLINICAL
TRIALS
Parties to litigation over investigational exclusions often find
themselves, literally as well as metaphorically, locked in mortal
combat in the courts. When potentially life-saving treatment is at
stake, trial courts are likely to rule in favor of the plaintiff. De-
fendants rarely appeal.13 Health plans have responded to this in a
variety of ways: they have strengthened the general investiga-
tional exclusion; developed procedure-specific exclusions for
certain treatments; been more selective in those cases they
choose to take to trial; and offered riders for investigational
treatments for inclusion at account option. All of these responses
have contributed to minimizing the element of uncertainty inher-
ent in benefit interpretation.
What these responses do not do, however, is answer the
fundamental question raised earlier: should health plans be in the
business of excluding all investigational treatment in the first
place? Expressed differently, is there a legitimate role for health
plans in paying for certain kinds of investigational treatment? If
so, what might this be? How might it be described for benefit
contract purposes?
With these questions in mind, it might be prudent for health
plans to begin to think about two categories of investigational
treatment, and pay separate attention to life-threatening diseases.
Where the disease is life-threatening, where conventional therapy
has failed, where, but for the investigational therapy, life expec-
tancy is limited, and where the investigational therapy is the only
possibility of preserving life, then health plans may wish to con-
sider developing humane, worthwhile alternatives to claims deni-
als. The funding of clinical trials would be a logical place to
begin.
The case law shows that the investigational exclusion is an
effective and appropriate barrier to payment for unorthodox treat-
13. See ADER & LEWIs, supra note 5.
W'mterl196]
HEALTH MATRIX
ments, such as coffee enemas and tomato therapies. 4 If this is all
it accomplishes, it is worth maintaining. However, for potentially
life-saving treatments, the case law suggests a trend that may
render standard medical coverage language insufficient to protect
against claims for investigational treatments, particularly in the
context of the terminally ill, where the treatment is prescribed by
legitimate providers and performed in leading institutions after
conventional therapy has failed.15 Even the finest of investiga-
tional exclusions and decision-making processes will face an up-
hill battle in court in life-threatening cases where the plan is
characterized as asking the court for a death sentence for the
subscriber.16
This is frustrating for health plans, many of which are not-
for-profit and which have in good faith set their premiums for
their products based on their contracts as written and the actua-
rial principles behind them. Moreover, despite misguided at-
tempts by plaintiffs and the press to depict health plans as latter-
day Scrooges, the reality is that health plans routinely pay enor-
mous sums for appropriate noninvestigational treatment. HDC-
ABMT, for example, is a therapy that is routinely paid for in the
treatment of at least six forms of cancers for which it is known
to be effective.
Therefore, the real issue to be addressed is not the enforce-
ability of the investigational exclusion, nor its wordsmithing, but
rather how medical research is to be financed. In earlier days,
cancer and heart disease were first in line for relatively abundant
research funds. Today, governmental sources are subject to
budget constraints; new diseases have unprecedented political
clout; burgeoning techno-med consumes an increasing proportion
of the health care dollar; and hospitals and physicians look to
medical research programs to solve patient census problems and
contribute to the bottom line. Health plans are now being tapped
to fill the void.
Is the cost of medical research now to be borne by health
plans? If so, then two conclusions follow. First, health care pre-
14. Requests for payment for these kinds of therapies are often denied by the plan's
medical director, without recourse to the courts. See Free v. Travellers, 551 F. Supp. 554 (D.
Md. 1982) (Laetrile treatments and vitamin regimens); Henne v. Mutual of Omaha, No. 81,
1359 (D. D.C. 1983) (unpublished opinion).
15. See Pirozzi, 741 F. Supp. at 586.
16. Id.
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miums could increase in the short run. Second, health plans
should begin to consider developing constructive payment mech-
anisms for investigational procedures, and to steer them into re-
search studies in a timely manner. For example, they might re-
write their benefit contracts to cover certain forms of
investigational treatment when provided in well-conceived
clinical trials under specified terms and conditions. Plans would
then be able to pool the resulting data and learn something for
the money expended. This approach would stimulate valuable re-
search and yield useful information. It would represent a new era
of collaboration and cooperation between payers and providers.
Above all, it would move the debate from the legal to the medi-
cal arena, where it belongs. A logical place to begin this process
would be for plans to engage in selective contracting with speci-
fied institutions for promising treatments (for example, Phase Ill
trials, representing a stage in the research that shows "substantial
promise"). This option would entail coverage only when the pro-
cedure was performed at specified institutions (or institutions that
met specified criteria).
Variations on this "Exclusive Provider Organization" theme,
and suggested contractual components of it, might include: con-
tributing to controlled clinical trials, under research protocols
(national if possible, to elicit comparable data), within a desig-
nated time frame, with data analysis, cost-sharing, and risk-
sharing. All of these components are designed to reinforce the
research and investigational nature of the procedure at issue.
Cost-sharing and risk-sharing might take a variety of forms (two-
way, plan-provider; or even three-way, plan/provider/subscriber ).
An example of such an approach is the Blue Cross and Blue
Shield System's Demonstration Project for HDC-ABMT for
breast cancer. The Blue Cross and Blue Shield Association, in
conjunction with the National Cancer Institute (NCI), is currently
sponsoring a Demonstration Project for HDC-ABMT for breast
cancer. The Blue Cross and Blue Shield Plans expect to contrib-
ute about $40 million to this randomized controlled clinical trial
over the next several years. The Demonstration Project supports
a series of four national Phase III trials. The NCI Trials are in-
tended for the eventual enrollment of 1500 women and are cur-
rently being conducted at eighty-six medical research institutions.
Blue Cross Blue Shield Association has contracts with forty-two
of these institutions. The research protocols governing each of
the NCI Trials were designed and approved by clinical trial co-
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operative groups, voluntary associations of cancer research insti-
tutions that conduct clinical trials executed uniformly among
member institutions. The research protocols have been approved
by the NCI, and the trials are randomized, so that the outcomes
of the treatments can be scientifically compared. Randomized tri-
als are ethical only where the researchers do not know whether
the experimental therapy, the standard therapy, or either therapy
is superior. This five-year Demonstration Project should be com-
pleted in 1996.
Another example of this kind of contracting is the Blue
Cross Blue Shield Association multiple myeloma trial program.
This program is modelled after the Breast Cancer Demonstration
Project, and includes unique contracts with a network of quali-
fied institutions, access to trials that are approved by a national
research organization, a fixed contribution rate negotiated with
each institution, and a centralized patient management and track-
ing system.
A final example of this kind of contracting is the Blue
Cross Blue Shield Association's response to the September, 1994
federal government mandate that all carriers in the Federal Em-
ployee Health Benefits Program cover high dose chemotherapy
with autologous bone marrow transplantation for three diagnoses:
breast cancer, multiple myeloma, and epithelial ovarian cancer.
The Blue Cross Blue Shield Association has developed a
"Clinical Trials Benefit," which covers these services, and al-
logeneic bone marrow transplants for multiple myeloma, when
performed in a clinical trial.
Clinical trials are the only way to resolve the relative effi-
cacy of new technologies and the only way to ensure that the pa-
tient is being treated as safely as possible by the most competent
physicians. If there is a point at which medicine, economics,
common law, and common sense intersect, then the funding of
clinical trials is that point. There are periods of scientific uncer-
tainty. These issues can only be resolved scientifically, if at all.
A court order or a state mandate to pay or an account mandate
to pay is not responsive to this dilemma.
This leaves one final issue: how should we select clinical
trials that are worth financing and incorporating into the health
care benefit? Not all clinical trials are of the same value. The tri-
als selected should be those that undergo the most rigorous pro-
tocol review process and receive thorough study oversight. For
HDC-ABMT for breast cancer, for example, the most strenuous
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level of protocol review and oversight is received by NCI-
sponsored therapeutic clinical trials conducted by the Clinical
Trials Cooperative Groups. Trials approved by other NCI pro-
grams or other research entities recognized by the NCI for Can-
cer Center support grants could be ranked second in importance
for health plan consideration. Trials approved only by a hospital
IRB and funded by the institution or pharmaceutical companies
or other local sponsors should be ranked lowest in importance
for health plan consideration.
Patients should always be treated in the highest "phase" of
a trial for which they are eligible, since this is the phase most
likely to yield a positive health outcome for that patient. Within
the hierarchy of trial phases, Phase M1 multi-center controlled tri-
als comparing investigational agents to standard therapy should
receive the highest priority for health plans. Phase II trials which
determine anti-tumor activity of agents generally in single-site
trials should be ranked second in importance to Phase Il trials
for health plan support. Phase I trials which attempt to establish
therapeutic effect and safe dosage should generally be supported
by the research sponsor and not by payors.
Some may argue that to embrace this approach in a benefit
contract would cause health care premiums to skyrocket. How-
ever, any such premium increases implemented in the short term
may well be tempered in the long run by the elimination of pay-
ment for procedures that the research determined were not effec-
tive, and by the swifter channeling of patients to treatments that
the research determined were effective. It is more productive for
health plans to steer their members into well-conceived clinical
trials than into ill-conceived judicial ones.
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